论文部分内容阅读
目的:研究司坦唑醇与吡拉西坦联用对D-半乳糖致大鼠股骨损伤的影响。方法:将大鼠随机分为正常对照组、模型组和联用组,每组10只,后2组皮下注射D-半乳糖(100mg·kg-1·d-1)建立骨质疏松症模型,建模后联用组灌胃给予司坦唑醇0.54mg·kg-1·d-1、吡拉西坦432mg·kg-1·d-1,连续给药14周。检测各组大鼠左侧股骨长和宽,干湿重/体重比和骨羟脯氨酸(Hyp)、骨钙、骨磷含量;右侧股骨最大载荷、弹性载荷、断裂载荷、刚性系数和弯曲能量。结果:与正常对照组比较,模型组大鼠股骨干湿重/体重比和骨钙、弹性载荷均明显降低(P<0.05),其余指标均无明显变化(P>0.05);与模型组比较,联用组股骨干重/体重比、弹性载荷均明显增加(P<0.05),其余指标无明显变化(P>0.05)。结论:司坦唑醇与吡拉西坦联用能有效预防D-半乳糖致大鼠股骨重量降低,增强骨强度。
Objective: To investigate the effect of combination of stanozolol and piracetam on femoral injury induced by D-galactose in rats. Methods: The rats were randomly divided into normal control group, model group and combination group, with 10 rats in each group. The latter two groups were given D-galactose (100 mg · kg-1 · d-1) subcutaneously to establish osteoporosis model After modeling, the rats in combination group were given gavage with 0.54 mg · kg -1 · d-1 of stanozolol and 432 mg · kg -1 · d -1 of piracetam. The left femur length and width, wet / dry weight / body weight ratio, hydroxyproline (Hyp), osteocalcin and osteoporotate content were measured in each group. The maximum, elastic, fracture load, Bend energy. Results: Compared with the normal control group, the femoral wet weight / body weight ratio and the calcium and elastic load of the model group were significantly decreased (P <0.05), and the other indexes had no significant changes (P> 0.05). Compared with the model group (P <0.05). The other indexes had no significant change (P> 0.05). Conclusion: The combination of stanozolol and piracetam can effectively prevent the weight of femur and decrease the bone mass of rats induced by D-galactose.